Zacks Investment Research·6 days ago
Medtronic (MDT) Stock Sinks As Market Gains: What You Should KnowMedtronic (MDT) reached $78.23 at the closing of the latest trading day, reflecting a -3.34% change compared to its last close.
Medtronic plc(MDT)Earnings, Financials & Key Ratios
MDT•NYSE
$83.06
22.3× P/E·Price updated Jul 6, 2026
AboutMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.Show more
- Revenue$36.36B+8.4%
- EBITDA$9.43B+6.9%
- Net Income$4.8B+3.0%
- EPS (Diluted)3.73+3.3%
- Gross Margin65.02%-0.5%
- EBITDA Margin25.92%-1.4%
- Operating Margin17.78%+0.2%
- Net Margin13.2%-5.0%
- ROE9.76%+3.3%
MDT Price & Volume
Medtronic plc (MDT) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Amidst Persistent Margin Volatility
Investment Thesis • Updated 2026Q4
VerdictNeutral
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Portfolio integration and competition
Key Thesis Takeaways
- Medtronic is demonstrating a promising top-line recovery with 9.9% year-over-year revenue growth in 2026Q4, supported by a robust 75.9% gross margin profile.
- However, investors should remain cautious as operating margins have fluctuated from 19.9% in 2025Q3 to 15.9% in 2026Q4, indicating that rising SG&A expenses and competitive pricing pressures may continue to weigh on bottom-line profitability.
- While the company maintains a healthy balance sheet with a 2.13 current ratio, the significant $42.6B goodwill concentration warrants ongoing scrutiny regarding potential impairment risks.
Verdict Logic
while the 9.9% revenue growth in 2026Q4 is encouraging, the inconsistent free cash flow margins and the 15.9% operating margin suggest that operational efficiency gains are not yet fully realized.
MDT Growth Metrics
Medtronic plc (MDT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.35%
5 Years3.84%
3 Years5.21%
TTM8.43%
Profit CAGR
10 Years3.1%
5 Years5.89%
3 Years8.5%
TTM2.94%
EPS CAGR
10 Years4.17%
5 Years7%
3 Years9.77%
TTM3.04%
Return on Capital
10 Years6.9%
5 Years7.18%
3 Years7.33%
Last Year8.08%
MDT Recent Earnings
Medtronic plc (MDT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 11/12 qtrs (92%)
Q3 2026Latest
Jun 3, 2026Metric
Actual
Est
EPS
$1.55+0.6%
$1.54
Rev
$9.8B+1.9%
$9.6B
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$1.36+1.5%
$1.34
Rev
$9.0B+1.2%
$8.9B
Q4 2025
Nov 18, 2025Metric
Actual
Est
EPS
$1.36+3.8%
$1.31
Rev
$9.0B+1.1%
$8.9B
Q3 2025
Aug 19, 2025Metric
Actual
Est
EPS
$1.26+2.4%
$1.23
Rev
$8.6B+2.4%
$8.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 3, 2026 | $1.55vs $1.54+0.6% | $9.8Bvs $9.6B+1.9% |
| Q1 2026 | Feb 17, 2026 | $1.36vs $1.34+1.5% | $9.0Bvs $8.9B+1.2% |
| Q4 2025 | Nov 18, 2025 | $1.36vs $1.31+3.8% | $9.0Bvs $8.9B+1.1% |
| Q3 2025 | Aug 19, 2025 | $1.26vs $1.23+2.4% | $8.6Bvs $8.4B+2.4% |
Based on last 12 quarters of dataView full earnings history →
Latest MDT News
Recent stock market news and headlines for Medtronic plc (MDT)
GuruFocus·6 days ago
Is Medtronic PLC (MDT) a Bargain After 3.3% Drop? GF Value Says UndervaluedOn June 30, 2026, Medtronic PLC (MDT) shares fell 3.3% today, bringing the current price to $78.23. The stock has traded between $73.31 and $106.33 over the pas
Zacks Investment Research·Jun 29, 2026
GMED vs. MDT: Which Medical Stock Has More Upside Potential?Globus Medical or Medtronic? See why Globus Medical's stronger growth, innovation and analyst upside may give it the edge despite a richer valuation.
The Motley Fool·Jun 23, 2026
2 High-Yield Dividend Stocks to Buy and Hold for a DecadeThese healthcare leaders have encountered challenges in recent years. However, they are slowly improving their businesses, partly through innovation.
Zacks Investment Research·Jun 22, 2026
Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Peers Comparison
Key metrics vs top competitors for Medtronic plc (MDT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $83.06 | $106.64B | 22.27 | 8.43% | 13.2% | 9.76% | 3.4% | |
| $95.63 | $166.57B | 25.71 | 5.67% | 13.91% | 12.09% | — | |
| $44.60 | $66.29B | 22.99 | 19.87% | 17.23% | 14.67% | — | |
| $95.18 | $54.8B | 52.01 | 11.55% | 17.34% | 10.54% | — | |
| $313.38 | $120.14B | 37.31 | 11.16% | 13.21% | 15.1% | — | |
| $89.76 | $17.58B | 25.28 | 7.2% | 9.05% | 5.77% | — |
Compare MDT vs Peers
Medtronic plc (MDT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDT SEC Filings & Documents
Medtronic plc (MDT) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Jun 3, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
Apr 27, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when MDT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDT Frequently Asked Questions
Medtronic plc (MDT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Medtronic plc's revenue?
Medtronic plc (MDT) reported $36.36B in revenue for fiscal year 2026. This represents a 1391% increase from $2.44B in 1997.
How fast is Medtronic plc growing?
Medtronic plc (MDT) grew revenue by 8.4% over the past year. This is steady growth.
Is MDT profitable?
Yes, Medtronic plc (MDT) is profitable, generating $4.80B in net income for fiscal year 2026 (13.2% net margin).
Dividend & Returns
Does MDT pay dividends?
Yes, Medtronic plc (MDT) pays a dividend with a yield of 3.40%. This makes it attractive for income-focused investors.
What is MDT's return on equity?
Medtronic plc (MDT) has a return on equity (ROE) of 9.8%. This is below average, suggesting room for improvement.
What is Medtronic plc's free cash flow?
Medtronic plc (MDT) generated $5.43B in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.